PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 18, 2026Pharmacoepidemiology and Drug Safety0 citationsOpen Access

Legal Basis and Regulatory Requirements for Utilizing Real‐World Evidence in Medical Product Regulatory Decision‐Making

View Full Paper
SPSungmin ParkEHE Han

Key Points

  • To examine the limitations and requirements for integrating real-world evidence (RWE) into regulatory processes for medical products.
  • Analyzed current regulatory frameworks for real-world evidence.
  • Identified key areas needing standardization, such as data quality and privacy regulations.
  • Proposed a registry certification system and review process for RWE research.
  • Highlighted the limited application of real-world evidence in regulatory decisions.
  • Provided recommendations for improving standards and reducing uncertainty around RWE use.
  • Suggested relaxing privacy regulations for specific government-managed registries.

Abstract

Key Points Real‐World Evidence (RWE) application in regulatory decisions remains limited. Clear standards are needed for data quality, transparency, and acceptable study designs for the use of RWE in regulatory contexts. Registry certification system and research plan review system for RWE research would help reduce regulatory uncertainty. To balance data protection and research utility, relaxation of privacy protection regulations for designated government‐managed registries could be considered.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Park et al. (2026) studied this question.

synapsesocial.com/papers/69e3211640886becb654052chttps://doi.org/10.1002/pds.70373
Ask AI
Helpful
Bookmark
Share
View Full Paper